ProteomeBinders
A Eurropean Infrastructure of Ligand Binding Molecules against the Human Proteome
ProteomeBinders is a European consortium proposing to establish a comprehensive infrastructure resource of binding molecules for detection of the human proteome, together with tools for their use and applications in studying proteome function and organisation.
This 4-year FP6 Research Infrastructures Coordination Action, started in March 2006, is funded with 1.8 M€ and links 25 EU and 2 USA partners, leaders in the area of binders and their applications. The project is coordinated by Dr Mike Taussig (Cambridge). We advocate the organisation of an infrastructure of binders, available at cost and with no restrictions for research use, for which we are applying for funding under FP7.
Currently there is no pan-European platform for the systematic development and quality control for these essential reagents. We aim to provide a set of consistently characterised binders, required to detect all the relevant human proteins in tissues and fluids in health and disease. As the size of the human proteome is at least an order of magnitude greater than the ~ 21.000 protein coding genes known to date, and as for many applications several binders against each target are needed, the scale of our project is potentially immense.
To date, antibodies are the most widely used protein-binders, but novel binder types based on alternative protein scaffolds, nucleic acids, peptides and chemical entities each have significant advantages and will be carefully evaluated. We will coordinate a European resource by integrating existing infrastructures, reviewing technologies and high-throughput production methods, standardising tools and applications, and establishing a database.
Being one of the largest genome-scale projects in Europe, aiming ultimately to produce and collect hundreds of thousands of specific binders, the ProteomeBinders resource will bring huge benefits for basic and applied research, impacting on healthcare, diagnostics, target discovery for drug intervention and therapeutics.
Partners
Department of Immunotechnology, Lund University, Sweden
Create Health - Strategic Centre for Clinical Cancer Research
Biosciences Division, Los Alamos National Laboratory, USA
University College, Dublin, Ireland
CNRS-Universités Aix-Marseille I & II, France
Department of Biotechnology, Technical University Braunschweig, Germany
Antibody Factory
Department of Chemical Biology, Helmholtz Centre for Infection Research, Braunschweig, Germany
ChemBioNet
Structural and Computational Biology Unit, EMBL, Heidelberg, Germany
ELM: Functional sites in proteins
phosphoELM: S/T/Y phosphorylation sites
SomaLogic Inc., Boulder CO, USA
Department of Biochemistry, University of Kassel, Germany
Proteomics Services, European Bioinformatics Institute, Hinxton, UK
HUPO-PSI: Proteomics Standards Initiative
Division of Functional Genome Analysis, German Cancer Research Center, Heidelberg, Germany
NMI, Tübingen, Germany
VTT Technical Research Centre of Finland, Turku, Finland
In-vitro ligand screening group, Max Planck Institute of Molecular Genetics, Berlin, Germany
Antibody Factory
Genomics & Proteomics Core Facilities, German Cancer Research Center, Heidelberg, Germany
Advanced Molecular Techniques in Genetics, Proteomics, and Medicine, The Rudbeck Laboratory, Uppsala University, Sweden
MolTools - developing tools for the postgenomic era
Center for Human and Clinical Genetics at the Leiden University Medical Center, Leiden, The Netherlands
imaGenes, Berlin, Germany
Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK
Dept. of Molecular and Cellular Interactions, VIB, Vrije Universiteit Brussel, Brussels, Belgium
School of Biotechnology, KTH, Stockholm, Sweden
Department of Biochemistry, University of Zurich, Switzerland
Medical Faculty University of Rijeka, Croatia
Laboratory of Analytical Chemistry and Biopolymer Structure Analysis, University of Konstanz, Germany
EMBL Monoclonal Antibody Core Facility, Monterotondo, Italy
Laboratoire Bordelais de Recherche en Informatique, Bordeaux, France
ProteomeBinders Bioinformatics Wiki
Biologische Chemie, Technische Universitaet Muenchen, Germany
Protein Technology Group,
Babraham Bioscience Technologies, Cambridge, UK
ESF Programme on Integrated Approaches for Functional Genomics
MolTools - developing tools for the postgenomic era
GSF - National Research Center for Environment and Health, Munich, Germany
Partner in Interaction Proteome (EU FP6 IP)
School of Biotechnology, KTH, Stockholm, Sweden
Human Protein Atlas: expression and localisation of proteins in human normal and cancer tissues
Speaker
Ronald Frank/Jutta Eichler
Coordinator
Babraham Bioscience Technologies Ltd (UK)
Homepage
Funding agency
EU-Projects